Article Text

PDF
Cohort study
Renin-angiotensin system blockers increase risk of angio-oedema
  1. Massimo Volpe,
  2. Giuliano Tocci
  1. Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psichology, University of Rome Sapienza, Sant'Andrea Hospital, Italy, and IRCCS Neuromed, Pozzilli (IS), Italy
  1. Correspondence to Professor Massimo Volpe
    Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psichology, University of Rome Sapienza, Sant'Andrea Hospital, via di Grottarossa 1035, Rome 00189, Italy; massimo.volpe{at}uniroma1.it

Statistics from Altmetric.com

Commentary on: OpenUrlCrossRefPubMedWeb of Science

Context

Hypertension continues to represent a major threat for people's health because it is associated with raised cardiovascular (CV) morbidity and mortality.1 As a consequence of the threatening role of hypertension, antihypertensive therapy has become one of the cornerstones of any CV prevention strategy. Solid evidence has accumulated over the last two decades of the beneficial role of renin-angiotensin system (RAS) blocking agents, including ACE inhibitors, angiotensin receptor blockers (ARBs) and, recently, direct renin inhibitors (DRIs), for not only lowering blood pressure, but also in …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.